LS1034細(xì)胞
器官來源： 盲腸
年限： Dukes' type C
ATCC Number： CRL-2158?
相關(guān)**： 大腸癌
是否是腫瘤細(xì)胞： 1
物種來源： 人
生長狀態(tài)： 貼壁生長
運(yùn)輸方式： 凍存運(yùn)輸
細(xì)胞形態(tài)： 上皮樣
數(shù)量： 大量
Designations: LS1034
Depositors: L Suardet
LS1034細(xì)胞Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: adherent, adherent
Organism: Homo sapiens
Morphology: epithelial
Source: Organ: cecum
Tumor Stage: Dukes' type C
Disease: colorectal carcinoma
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Isolation: Isolation date: 1989
Tumorigenic: Yes
Oncogene: p53 + (mutated, Gly --> Ser mutation at position 245), APC (mutated, deletion, GAAAAGATT --> GATT at codon 1309)
Antigen Expression: carcinoembryonic antigen (CEA); ICAM-1; HLA class I positive
DNA Profile (STR): LS1034細(xì)胞Amelogenin: X,Y
CSF1PO: 11,12
D13S317: 12
D16S539: 9,11
D5S818: 12,13
D7S820: 8,12
THO1: 7
TPOX: 9,11
vWA: 17
Cytogenetic Analysis: modal number = 77, YY; seven markers involving chromosomes 1, 7, 14, X, and 18 were recognized. The other chromosomes involved could not be properly identified.; Monosomy 7 and monosomy 14 were present in all 15 metaphases analyzed. No normal chromosomes 5 or 18 were observed.
Age: 54 years
Gender: male
Ethnicity: Caucasian
Comments: LS1034 is a colorectal carcinoma cell line isolated in 1989 from a primary tumor biopsy from a 54-year old Caucasian male patient diagnosed with Dukes' Type C, moderately to poorly differentiated cecal carcinoma.
LS1034細(xì)胞More than 90% of LS1034 cells express surface CEA.
The cells express the major histocompatibility (MHC) class I antigens and beta 2 microglobulin, but class II antigens, (HLA-DR, DQ, and DP) were not detected.
No measurable amount of latent transforming growth factor beta-1 (TGF beta-1) is secreted.
Picomolar concentrations of TGF beta-1, TGF beta-2, and TGF beta-3 inhibit the proliferation of LS1034 cells.
LS1034 cells are multidrug resistant (MDR), and can proliferate in serum free medium.
The patient did not exhibit familial adenomatous polyposis (FAP) and normal tissue did not have the deletion in the APC gene.
The colony forming efficiency was 3% in methylcellulose medium containing 5% fetal bovine serum, and the clonogenicity is increased 600% in serum free methylcellulose as compared to semisolid medium containing serum.
A culture submitted to the ATCC in September 1994 was found to be contaminated with mycoplasma, and was cured by a 21 day treatment with BM Cycline.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Protocol:
Remove and discard culture medium.
Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37?C to facilitate dispersal.
Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
Add appropriate aliquots of the cell suspension to new culture vessels.
Incubate cultures at 37?C.
Subcultivation Ratio: A subcultivation ratio of 1:3 is recommended
Medium Renewal: LS1034細(xì)胞Twice per week
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Doubling Time: 33 hrs
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 23099: Suardet L, et al. Responsiveness of three newly established human colorectal cancer cell lines to transforming growth factors beta 1 and beta 2. Cancer Res. 52: 3705-3712, 1992. PubMed: 1617643
23339: Burmester JK, et al. Characterization of distinct functional domains of transforming growth factor beta. Proc. Natl. Acad. Sci. USA 90: 8628-8632, 1993. PubMed: 7690965
23418: Li CY, et al. Potential role of WAF1/Cip1/p21 as a mediator of TGF-beta cytoinhibitory effect. J. Biol. Chem. 270: 4971-4974, 1995. PubMed: 7890601
26172: Cottrell S, et al. Molecular analysis of APC mutations in familial adenomatous polyposis and sporadic colon carcinomas. Lancet 340: 626-630, 1992. PubMed: 1355210
